Idorsia-led Portfolio
Compound | Mechanism of action | Target indication | Status | More Information |
QUVIVIQ™ (daridorexant) |
Dual orexin receptor antagonist |
Insomnia |
Commercially available in the US, Germany, Italy, Switzerland, |
|
Aprocitentan |
Dual endothelin receptor antagonist |
Resistant hypertension |
NDA under review in the US, MAA under review in the EU, |
|
Lucerastat |
Glucosylceramide synthase inhibitor |
Fabry disease |
Phase 3 primary endpoint not met, |
|
ACT-1004-1239 |
ACKR3 / CXCR7 antagonist |
Multiple sclerosis and other demyelinating diseases |
Phase 2 in preparation |
|
Sinbaglustat |
GBA2/GCS inhibitor |
Rare lysosomal storage disorders |
Phase 1 complete |
|
ACT-777991 |
CXCR3 antagonist |
Recent-onset Type 1 diabetes |
Phase 1 complete |
|
ACT-1014-6470 |
C5aR1 antagonist |
Immune-mediated disorders |
Phase 1 |
|
IDOR-1117-2520 |
Undisclosed |
Immune-mediated disorders |
Phase 1 |
|
IDOR-1134-2831 |
Synthetic glycan vaccine |
Clostridium difficile infection |
Phase 1 in preparation |